Top Markets
#1 Pleasing Gold Pleasing Gold +468.74%
#2 Islamic Coin Islamic Coin +154.24%
#3 PulseChain PulseChain +52.83%
#4 BOOK OF MEME BOOK OF MEME +47.04%
#5 DogBull DogBull +35.86%
#6 ORDI ORDI +20.39%
#7 Nockchain Nockchain +18.86%
#8 PondCoin PondCoin +17.46%
#9 rsERG rsERG +17.37%
#10 Merlin's Seal BTC Merlin's Seal BTC +16.35%
Coin of the day
Pleasing Gold Pleasing Gold
Settings
Language
ENGLISH
Currency
USD
Theme
NurExone Biologic Inc. NurExone Biologic Inc.

NurExone Biologic Inc.

NRX
Rank in Stocks #27124
NurExone Biologic Inc., a pharmaceutical technology company, develops a... NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury. The company was founded on June 27, 2011 and is headquartered in Toronto, Canada.
Share Price
$0.47705898
Last synced: 2026-08-19
Market Cap
$35.01M
Change (1 day)
8.33%
Change (1 year)
-16.23%
Country
CA
Trade NurExone Biologic Inc. (NRX)

Category

Healthcare
P/S ratio for NurExone Biologic Inc. (NRX)
P/S ratio as of 2026 TTM: 0
According to NurExone Biologic Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for NurExone Biologic Inc. from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH